Sickle Cell Disease Drugs Market Analysis

The market is segmented by treatment type into blood transfusion, stem cell transplant, and pharmacotherapy, out of which, the stem cell transplant segment is anticipated to hold the largest share in the market during the forecast period as stem cell transplant is the only treatment method that can permanently treat sickle cell disease. This is estimated to increase the demand for stem cell transplant among the patients. Based on end-user, the market is segmented into hospitals, home care, specialty clinics, and others out of which hospital segment is anticipated to hold the largest market share throughout the forecast period owing to the increasing patient pool of sickle cell disease and new advancements in the treatment technology.

Our in-depth analysis of the global market includes the following segments:

Treatment Type

Blood Transfusion
Stem Cell Transplant
Pharmacotherapy

Disease Type

Sickle Cell Anemia
Sickle Hemoglobin-C
Others

End-User

Hospitals
Homecare
Specialty Clinic
Others

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of sickle cell disease drugs is evaluated at USD 3.05 billion.

Sickle Cell Disease Drugs Market size was over USD 2.71 billion in 2023 and is poised to cross USD 18.45 billion by 2036, growing at more than 15.9% CAGR during the forecast period i.e., between 2024-2036. Rising prevalence of sickle cell disease, such as, sickle cell anemia, due to genetic mutation will boost the market growth.

North America is anticipated to account for largest revenue share by 2036, on the back of advanced medical facilities, and research and development activities.

The major players in the market are Medunik USA Inc., Emmaus Life Sciences, Inc., CellSeed, Inc., Global Blood Therapeutics, Inc., Sio Gene Therapies Ltd., Imara, Inc., Modus Therapeutics AB, Bluebird bio, Inc., Vertex Pharmaceuticals Incorporated, and others.

Sickle Cell Disease Drugs Market Analysis